首页> 美国卫生研究院文献>other >Hyper-CVAD + ponatinib vs. hyper-CVAD + dasatinib as frontline therapy for Ph-positive ALL: a propensity score analysis

【2h】

Hyper-CVAD + ponatinib vs. hyper-CVAD + dasatinib as frontline therapy for Ph-positive ALL: a propensity score analysis

机译：Hyper-CVAD + ponatinib与Hyper-CVAD + dasatinib作为Ph阳性ALL的一线治疗：倾向评分分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundThe clinical efficacy of hyper-CVAD (HCVAD) + ponatinib has not been compared to that of HCVAD + dasatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in a randomized clinical trial.

机译：背景在一项随机临床试验中，尚未将高CVAD（HCVAD）+ ponatinib的临床疗效与HCVAD + dasatinib在费城染色体阳性的急性淋巴细胞白血病（Ph + ALL）患者中进行比较。

著录项

期刊名称 other
作者
Koji Sasaki; Elias Jabbour; Farhad Ravandi; Nicholas J. Short; Deborah Thomas; Guillermo Garcia-Manero; Naval Daver; Tapan Kadia; Marina Konopleva; Nitin Jain; Ghayas C. Issa; Vicki Jeanis; Gal Moore; Rebecca Garris; Naveen Pemmaraju; Jorge E. Cortes; Susan OBrien; Hagop Kantarjian;
展开▼
作者单位

展开▼
年(卷),期 -1(122),23
年度 -1
页码 3650–3656
总页数 12
原文格式 PDF
正文语种
中图分类
关键词
Philadelphia chromosome acute lymphoblastic leukemia hyper-CVAD ponatinib dasatinib;

机译：费城染色体;急性淋巴细胞白血病;高CVAD;ponatinib;dasatinib;

相似文献

外文文献
中文文献
专利

1. Hyper-CVAD Plus Ponatinib Versus Hyper-CVAD Plus Dasatinib as Frontline Therapy for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Propensity Score Analysis [J] . Sasaki Koji, Jabbour Elias J., Ravandi Farhad, Cancer: A Journal of the American Cancer Society . 2016,第23期

机译：Hyper-CVAD加波纳替尼与Hyper-CVAD加达沙替尼作为费城染色体阳性急性淋巴细胞白血病患者的一线治疗：倾向评分分析
2. Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Propensity Score Analysis [J] . Sasaki Koji, Kantarjian Hagop M., Short Nicholas J., Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：Inotuzumab ozogamicin与低强度化疗（迷你超级CVD）相结合。标准密集化疗（超CVAD）作为费城染色体阴性急性淋巴细胞白血病（ALL）的老年患者的前线治疗：倾向分数分析
3. A Propensity Score Matching Analysis of Dasatinib and Nilotinib as a Frontline Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase [J] . Takahashi Koichi, Kantarjian Hagop M., Yang Yulong, Cancer: A Journal of the American Cancer Society . 2016,第21期

机译：达沙替尼和尼洛替尼作为慢性期慢性粒细胞白血病患者的一线治疗的倾向得分匹配分析
4. The Effect Analysis of Textile Intangible Cultural Heritage on Tourist Income based on Propensity Score Matching [C] . Hong Zhao, Wenya Dai International Conference on Education, Management Science and Economics . 2019

机译：基于倾向得分匹配的纺织不源文化遗产对旅游收入的影响分析
5. Outcomes of Clostridium difficile Infection caused by the NAP1/BI/027 strain vs. Non Hypervirulent Strains: A Propensity Score Analysis. [D] . Epstein, Lauren. 2013

机译：由NAP1 / BI / 027菌株与非高毒力菌株引起的艰难梭菌感染的结果：倾向评分分析。
6. First Report of a Phase II Prospective Study of Combination of Hyper-CVAD with Ponatinib in Frontline Therapy of Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia [O] . Elias Jabbour, Hagop Kantarjian, Farhad Ravandi, -1

机译：Hyper-CVAD与Ponatinib联合用于费城染色体阳性急性淋巴细胞性白血病一线治疗的II期前瞻性研究的首次报道
7. A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase [O] . Koichi Takahashi, Hagop M. Kantarjian, Yulong Yang, 2016

机译：Dasatinib和Nilotinib作为慢性磷酸慢性骨髓白血病患者的前线治疗倾向评分匹配分析

Hyper-CVAD + ponatinib vs. hyper-CVAD + dasatinib as frontline therapy for Ph-positive ALL: a propensity score analysis

摘要

著录项

相似文献

相关主题

期刊订阅